# Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy

> **NCT00549692** · PHASE3 · COMPLETED · sponsor: **Kuhnil Pharmaceutical Co., Ltd.** · enrollment: 152 (actual)

## Conditions studied

- IgA Nephropathy

## Interventions

- **DRUG:** Omega-3 fatty acid ethylester90

## Key facts

- **NCT ID:** NCT00549692
- **Lead sponsor:** Kuhnil Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2012-08
- **Final completion:** 2012-09
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2012-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00549692

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00549692, "Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00549692. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*